Martingale Asset Management L P Travere Therapeutics, Inc. Transaction History

Martingale Asset Management L P

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.26 - $8.28 $59,459 - $93,597	11,304 New	11,304 $92,000
Q3 2023 Nov 14, 2023	SELL	$7.64 - $17.25 $189,472 - $427,800	-24,800 Reduced 55.11%	20,203 $180,000
Q2 2023 Aug 11, 2023	SELL	$15.3 - $22.61 $71,910 - $106,267	-4,700 Reduced 9.46%	45,003 $691,000
Q1 2023 May 12, 2023	BUY	$17.82 - $22.89 $3,564 - $4,578	200 Added 0.4%	49,703 $1.12 Million
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $202,948 - $287,226	10,988 Added 28.53%	49,503 $1.04 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $534,146 - $667,508	23,315 Added 153.39%	38,515 $950,000
Q2 2022 Aug 11, 2022	BUY	$20.94 - $30.01 $318,288 - $456,152	15,200 New	15,200 $368,000
Q2 2021 Aug 13, 2021	SELL	$14.11 - $26.4 $262,657 - $491,436	-18,615 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$23.37 - $31.77 $32,718 - $44,478	-1,400 Reduced 6.99%	18,615 $464,000
Q4 2020 Feb 10, 2021	BUY	$19.17 - $27.87 $383,687 - $557,818	20,015 New	20,015 $545,000

214

94.3M

1.2M

778K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.32B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.